Search

Multi-center acute myeloid leukemia study update, December 2023

A project update from Prof Maria Teresa Voso. We successfully completed the data collection and harmonization phases, and are now in the process of data analysis.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

Open Access: the ‘Plan S’

 

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.

Read more

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Personalized medicine promises radical improvements to healthcare in Europe

And the precision that personalised medicine will bring good prospects for better use of resources.

Read more